Endocrinology, Vol 137, 4139-4144, Copyright © 1996 by Endocrine Society

ARTICLES

Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia

GL Evans, HU Bryant, DE Magee and RT Turner
Department of Orthopedics, Mayo Clinic, Rochester, Minnesota 55905, USA.

Estrogen (E) treatment has proven to be effective in preventing bone loss after menopause with, however, some undesirable side effects. Many of these side effects are related to the hormone's actions on reproductive tissues. Raloxifene is an organ-selective estrogen agonist that prevents acute cancellous osteopenia in ovariectomized (OVX'd) growing rats. The effects of raloxifene on adult rats with established bone loss are not known. We now compare the dose response effects of 4 months of treatment with raloxifene and estrogen in 8-month-old rats that had been OVX'd 2 months before treatment. OVX resulted in increased body weight, uterine atrophy and severe cancellous bone loss. Estrogen resulted in a dose-dependent increase in uterine weight in OVX'd rats whereas raloxifene did not promote uterine growth. Both treatments reduced body weight and serum cholesterol. Raloxifene and estrogen were each effective in stabilizing cancellous bone by preventing additional cancellous bone loss, but neither treatment replaced lost bone. These findings provide further evidence that raloxifene is a much more potent estrogen agonist on the skeleton and liver than on the uterus.

This article has been cited by other articles:

				S. J. Warden, L. K. Saxon, A. B. Castillo, and C. H. Turner Knee ligament mechanical properties are not influenced by estrogen or its receptors Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E1034 - E1040. [Abstract] [Full Text] [PDF]

				K. M. Prestwood, M. Gunness, D. B. Muchmore, Y. Lu, M. Wong, and L. G. Raisz A Comparison of the Effects of Raloxifene and Estrogen on Bone in Postmenopausal Women J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2197 - 2202. [Abstract] [Full Text]

				J. Ashby Validation of In Vitro and In Vivo Methods for Assessing Endocrine Disrupting Chemicals Toxicol Pathol, May 1, 2000; 28(3): 432 - 437. [Abstract] [PDF]

				W. Khovidhunkit and D. M. Shoback Clinical Effects of Raloxifene Hydrochloride in Women Ann Intern Med, March 2, 1999; 130(5): 431 - 439. [Abstract] [Full Text] [PDF]

				M. Sato, G. Q. Zeng, E. Rowley, and C. H. Turner LY353381{middle dot}HCl: An Improved Benzothiophene Analog with Bone Efficacy Complementary to Parathyroid Hormone-(1-34) Endocrinology, November 1, 1998; 139(11): 4642 - 4651. [Abstract] [Full Text] [PDF]

				J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]

				M. Sato, G. Q. Zeng, and C. H. Turner Biosynthetic Human Parathyroid Hormone (1-34) Effects on Bone Quality in Aged Ovariectomized Rats Endocrinology, October 1, 1997; 138(10): 4330 - 4337. [Abstract] [Full Text] [PDF]